|
AU2005203518A1
|
|
Pharmaceutical and nutritional compositions containing essential fatty acids and homocysteine-lowering agents
|
|
GB0428318D0
|
|
Pharmaceutical compositions comprising EPA and methods of use
|
|
GB0228079D0
|
|
Huntington's Disease
|
|
GB0221480D0
|
|
Treatment of anorexia nervosa (AN) and bulimia
|
|
CA2449199A1
|
|
Coenzyme q and eicosapentaenoic acid (epa)
|
|
GB0202900D0
|
|
Novel formulations of drugs
|
|
GB0123446D0
|
|
Coenzyme Q and EPA
|
|
YU99602A
|
|
Therapeutic combinations of fatty acids
|
|
GB0113104D0
|
|
Coenzyme Q and EPA
|
|
GB0111282D0
|
|
Potentiation of therapeutic effects of fatty acids
|
|
IL147556D0
|
|
Pharmaceutical and nutritional compositions containing essential fatty acids and homocysteine-lowering agents
|
|
AU2931000A
|
|
Diagnostic test
|
|
HU0700811D0
|
|
Highly purified ethyl epa and other epa derivatives for psychiatric and neurological disorders
|
|
HU0105215A2
|
|
Use of highly purified ethyl epa and other epa derivatives for disorders
|
|
AU3063800A
|
|
Drugs for treatment of psychiatric and brain disorders
|
|
GB9924172D0
|
|
Combination formulations for fatigue, head injury and strokes
|
